{"id":82397,"date":"2026-05-06T16:28:52","date_gmt":"2026-05-06T10:58:52","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=82397"},"modified":"2026-05-06T16:28:53","modified_gmt":"2026-05-06T10:58:53","slug":"emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/","title":{"rendered":"Emcure Q4 Results FY26: PAT Rs 243 Crore Up 24 Percent, Revenue Rs 2470 Crore Up 17 Percent"},"content":{"rendered":"<div class=\"meta-block\">\u00a0<\/div>\n<p>Emcure Q4 results FY26 reported consolidated net profit of Rs 243.40 crore for the quarter ended March 31, 2026, up 23.57 percent year on year from Rs 197.23 crore in Q4 FY25. The Emcure Q4 results revenue from operations grew 16.70 percent year on year to Rs 2,469.7 crore, reflecting growth across India&#8217;s branded pharma market and international markets including the US, Europe, and Africa.<\/p>\n<p>The Emcure Q4 results mark the company&#8217;s continued execution on its branded pharmaceutical strategy post the FY25 IPO. Emcure Q4 results management highlighted strong performance in the Gynaecology, Haematology, and Cardiovascular therapy areas in India, which form the company&#8217;s brand moat. International markets, including US generic filings and Europe partnership revenues, also contributed positively to Emcure Q4 results top-line growth.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get Free Stock Recommendations on Univest<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#Emcure_Pharmaceuticals_Q4_FY26_Results_at_a_Glance\" title=\"Emcure Pharmaceuticals Q4 FY26 Results at a Glance\">Emcure Pharmaceuticals Q4 FY26 Results at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#Key_Highlights_from_Emcure_Q4_results\" title=\"Key Highlights from Emcure Q4 results\">Key Highlights from Emcure Q4 results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#23_Percent_PAT_Growth_Reflects_India_Branded_Strength_in_Emcure_Q4_Results\" title=\"23 Percent PAT Growth Reflects India Branded Strength in Emcure Q4 Results\">23 Percent PAT Growth Reflects India Branded Strength in Emcure Q4 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#Revenue_of_Rs_2470_Crore_Up_17_Percent_Confirms_Scale_in_Emcure_Q4_Results\" title=\"Revenue of Rs 2470 Crore Up 17 Percent Confirms Scale in Emcure Q4 Results\">Revenue of Rs 2470 Crore Up 17 Percent Confirms Scale in Emcure Q4 Results<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#What_Drove_Emcure_Pharmaceuticals_Q4_FY26_Performance\" title=\"What Drove Emcure Pharmaceuticals Q4 FY26 Performance\">What Drove Emcure Pharmaceuticals Q4 FY26 Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#Outlook_for_FY27\" title=\"Outlook for FY27\">Outlook for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#What_was_the_Emcure_Q4_results_FY26_net_profit\" title=\"What was the Emcure Q4 results FY26 net profit?\">What was the Emcure Q4 results FY26 net profit?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#What_are_the_key_therapies_driving_Emcure_Q4_results_FY26\" title=\"What are the key therapies driving Emcure Q4 results FY26?\">What are the key therapies driving Emcure Q4 results FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#What_is_the_outlook_after_Emcure_Q4_results_FY26\" title=\"What is the outlook after Emcure Q4 results FY26?\">What is the outlook after Emcure Q4 results FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#What_was_the_Emcure_Q4_results_FY26_revenue\" title=\"What was the Emcure Q4 results FY26 revenue?\">What was the Emcure Q4 results FY26 revenue?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q4-results-fy26-pat-rs-243-crore\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_Q4_FY26_Results_at_a_Glance\"><\/span><strong>Emcure Pharmaceuticals Q4 FY26 Results at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26<\/th>\n<th>Change \/ Context<\/th>\n<\/tr>\n<tr>\n<td>Q4 Consolidated PAT<\/td>\n<td>Rs 243.40 crore<\/td>\n<td>+23.57% YoY vs Rs 197.23 crore<\/td>\n<\/tr>\n<tr>\n<td>Q4 Revenue from Operations<\/td>\n<td>Rs 2,469.7 crore<\/td>\n<td>+16.70% YoY<\/td>\n<\/tr>\n<tr>\n<td>India Branded Business<\/td>\n<td>Key revenue driver<\/td>\n<td>Gynaecology, Haematology, CVD<\/td>\n<\/tr>\n<tr>\n<td>International Revenue<\/td>\n<td>Growing contribution<\/td>\n<td>US, Europe, Africa markets<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>Margins maintained<\/td>\n<td>Operating leverage on scale<\/td>\n<\/tr>\n<tr>\n<td>FY26 Growth Momentum<\/td>\n<td>Double digit revenue CAGR<\/td>\n<td>Post-IPO growth trajectory<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Track live Emcure Pharmaceuticals financials, analyst ratings and peer comparisons on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Highlights_from_Emcure_Q4_results\"><\/span><strong>Key Highlights from Emcure Q4 results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"23_Percent_PAT_Growth_Reflects_India_Branded_Strength_in_Emcure_Q4_Results\"><\/span><strong>23 Percent PAT Growth Reflects India Branded Strength in Emcure Q4 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Emcure Q4 results PAT of Rs 243.40 crore, up 23.57 percent, reflects strong performance in branded therapy areas that command pricing power and prescription loyalty. The Gynaecology franchise, where Emcure holds number 1 or 2 positions in several therapeutic sub-categories, continued to deliver consistent double-digit growth embedded in Emcure Q4 results. The Haematology segment, which covers iron deficiency anaemia products, also benefited from expanding diagnosis rates and government healthcare programs.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_of_Rs_2470_Crore_Up_17_Percent_Confirms_Scale_in_Emcure_Q4_Results\"><\/span><strong>Revenue of Rs 2470 Crore Up 17 Percent Confirms Scale in Emcure Q4 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Emcure Q4 results revenue of Rs 2,469.7 crore, up 16.70 percent year on year, demonstrates the company&#8217;s ability to grow across both India and international markets simultaneously. Post-IPO investments in field force expansion and new product launches have been contributing to the Emcure Q4 results acceleration. The international business, including Zuventus Healthcare subsidiary revenues in Europe and US partnered generic revenues, added a meaningful incremental revenue layer to Emcure Q4 results.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Drove_Emcure_Pharmaceuticals_Q4_FY26_Performance\"><\/span><strong>What Drove Emcure Pharmaceuticals Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Emcure Q4 results performance was driven by India&#8217;s branded pharmaceutical market recovery, prescription volume growth in Gynaecology and Haematology, and international market contribution from US generic launches and European partnership revenues. The company&#8217;s post-IPO investments in digital marketing, field force expansion, and new product registrations in key markets are reflected in the Emcure Q4 results revenue trajectory. EBITDA margin maintenance despite higher marketing investments reflects the branded pricing power embedded in Emcure Q4 results quality.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Outlook_for_FY27\"><\/span><strong>Outlook for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following Emcure Q4 results, FY27 outlook is constructive with continued branded expansion in India, US generic filings contributing incrementally, and African market development. Management at Emcure Q4 results briefing highlighted a pipeline of chronic therapy products in CNS and Oncology that could enter India launch in FY27. Analyst consensus targets for Emcure post Q4 results range between Rs 1,600 and Rs 2,000.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Emcure Q4 results FY26 confirm 23.57 percent PAT growth to Rs 243.40 crore and 16.70 percent revenue growth to Rs 2,469.7 crore, driven by branded therapy leadership in Gynaecology, Haematology, and Cardiovascular segments. Emcure Q4 results position the company as a strong post-IPO compounder. Track live Emcure Q4 results data on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest iOS App<\/strong><\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest Android App<\/strong><\/a> for live Emcure Q4 results tracking and expert research.<\/p>\n<p><em>Disclaimer: This article is for informational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making investment decisions.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Emcure_Q4_results_FY26_net_profit\"><\/span><strong>What was the Emcure Q4 results FY26 net profit?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Emcure Q4 results FY26 reported consolidated PAT of Rs 243.40 crore, up 23.57 percent year on year from Rs 197.23 crore. Revenue grew 16.70 percent to Rs 2,469.7 crore in the Emcure Q4 results quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_therapies_driving_Emcure_Q4_results_FY26\"><\/span><strong>What are the key therapies driving Emcure Q4 results FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key therapies driving Emcure Q4 results include Gynaecology, Haematology, and Cardiovascular therapy areas in India where the company holds top market positions. International markets in US generics and Europe partnerships also contributed to Emcure Q4 results growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_outlook_after_Emcure_Q4_results_FY26\"><\/span><strong>What is the outlook after Emcure Q4 results FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Following Emcure Q4 results, FY27 outlook is positive with chronic therapy launches in CNS and Oncology in India, US generic pipeline contributions, and Africa market development. Analyst targets range Rs 1,600 to Rs 2,000 post Emcure Q4 results.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Emcure_Q4_results_FY26_revenue\"><\/span><strong>What was the Emcure Q4 results FY26 revenue?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Emcure Q4 results FY26 revenue from operations was Rs 2,469.7 crore, up 16.70 percent year on year, driven by India branded pharmaceutical growth and international market expansion.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-nuvoco-share-price-falling-key-reasons-2026\">Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-capacite-share-price-falling-key-reasons-2026\">Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-psp-projects-share-price-falling-key-reasons-2026\">Why Is PSP Projects Share Price Falling Key Reasons 2026<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Emcure Q4 results FY26: consolidated PAT Rs 243.40 crore up 23.57%, revenue Rs 2,469.7 crore up 16.70% YoY. India and international markets both growing. Strong pharma delivery.<\/p>\n","protected":false},"author":26,"featured_media":82687,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-82397","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778065153:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["68"],"rank_math_focus_keyword":["Emcure Q4"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Emcure Q4 Results FY26 PAT Rs 243 Crore Up 23 Percent Revenue Rs 2470 Crore Up 17 Percent"],"rank_math_description":["Emcure Q4 results FY26: consolidated PAT Rs 243.40 crore up 23.57%, revenue Rs 2,469.7 crore up 16.70% YoY. India and international markets both growing. Strong pharma delivery."],"_thumbnail_id":["82687"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["10476"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/06162821\/Emcure-Q4-Results-FY26.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=82397"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82397\/revisions"}],"predecessor-version":[{"id":82689,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82397\/revisions\/82689"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/82687"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=82397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=82397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=82397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}